All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB, Protopopescu C, Stewart AC, van Santen DK, Klein MB, Jarrin I, Berenguer J, Wittkop L, Salmon D, Rauch A, Prins M, van der Valk M, Sacks-Davis R, Hellard ME, Carrieri P, Lacombe K; on behalf of the InCHEHC Collaboration
Global Infectious Disease Threats Hepatitis C HIV + AIDS
Risk of primary incident hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia from 2016 to 2020.
Harney BL, Sacks-Davis R, Agius P, van Santen DK, Traeger MW, Wilkinson AL, Asselin J, Fairley CK, Roth N, Bloch M, Matthews GV, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS
Global Infectious Disease Threats Hepatitis C
Innovation is needed to increase viral hepatitis testing globally.
Hellard ME, Pedrana A.
Hepatitis B Hepatitis C
Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020.
Harney BL, Sacks-Davis R, van Santen DK, Traeger MW, Wilkinson AL, Asselin J, Fairley CK, Roth N, Bloch M, Matthews GV, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS
Global Infectious Disease Threats Hepatitis C HIV + AIDS
Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020.
Harney BL, Sacks-Davis R, van Santen DK, Traeger MW, Wilkinson AL, Asselin J, Fairley CK, Roth N, Bloch M, Matthews GV, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS.
Hepatitis C HIV + AIDS
Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB, Whitton B, Anderson J, Cogger S, Vella-Horne D, Penn M, Weeks T, Elmore K, Pemberton D, Winter RJ, Papaluca T, Howell J, Hellard M, Stoové M, Wilson D, Pedrana A, Doyle JS, Clark N, Holmes JA, Thompson AJ.
Hepatitis C Injecting Drug Use